Date: 2014-08-05
Type of information: Publication of results in a medical journal
phase: preclinical
Announcement: publication of results in Critical Care Medicine
Company: Silence Therapeutics (UK)
Product: Atu111
Action
mechanism: RNAi. Atu111 targets the endothelial expression of Angiopoietin-2 (Ang-2), an antagonistic ligand of Tie-2 signalling, which is implicated in progressing endothelial dysfunction in the context of disease pathogenesis for acute lung injury or sepsis. The product uses the DACC drug delivery system which is a lipid-based formulation which is designed to tackle lung-specific diseases. Delivered by blood infusion, the DACC particles become trapped in the small blood vessels of the lungs.
Disease: sepsis
Therapeutic area: Inflammatory diseases
Country:
Trial details:
Latest
news: * On August 5, 2014, Silence Therapeutics announced that pre-clinical study data on the use of its Atu111 RNAi (RNA interference) technology in sepsis has been published in Critical Care Medicine (Lung-targeted RNA-interference against Angiopoietin-2 ameliorates multi-organ dysfunction and death in sepsis). The study found that treatment with Atu111 lung endothelium-targeted RNAi using the Company’s proprietary DACC delivery system ameliorated the severity of illness resulting from sepsis and improved survival, both as through pre-treatment and as a rescue intervention. Atu111 specifically targeted Angiopoietin 2, a vascular inflammatory agent, and was successful in reducing Angiopoietin 2 expression in septic subjects by up to 73.8%.
This data was also presented in a poster session at the Gordon Research Conference on Endothelial Cell Phenotypes in Health & Disease in Girona, Spain, on 9 and 10 July 2014.
